Endothelial progenitor cells (EPCs) contribute to postnatal neovascularization. Risk factors for coronary artery disease reduce the number of EPCs in humans. Since EPC apoptosis might be a potential mechanism to regulate the number of EPCs, we investigated the effects of oxidative stress and HMG-CoA-reductase inhibitors (statins) on EPC apoptosis. Atorvastatin, mevastatin, or VEGF prevented EPC apoptosis induced by H 2 O 2 . The antiapoptotic effect was reversed by inhibition of the PI3K/Akt pathway. Forkhead transcription factors (FOXO1, FOXO3a, FOXO4) exert proapoptotic effects and are phosphorylated and, thereby, inactivated by Akt. Therefore, we elucidated the involvement of forkhead transcription factors. Atorvastatin induced the phosphorylation of the predominant forkhead factor FOXO4 in EPCs. In addition, atorvastatin reduced the expression of the proapoptotic forkhead-regulated protein Bim in a PI3K-dependent manner. Consistently, overexpression of FOXO4 activated the Bim promoter as determined by reporter gene expression and stimulated the expression of Bim, resulting in an increased EPC apoptosis. Statins failed to prevent EPC apoptosis induced by overexpression of Bim or nonphosphorylatable FOXO4, suggesting that the protective effects of statins depend on this pathway. In summary, our results show that FOXO-dependent expression of Bim plays a pivotal role for EPC apoptosis. Statins reduce oxidative stress-induced EPC apoptosis, inactivate FOXO4, and down-regulate Bim. are positive for CD34 or the more immature marker protein CD133 and the endothelial marker proteins such as VEGF receptor 2 (KDR), von Willebrand factor, VE-cadherin, eNOS, take-up of diacetylated LDL, and lectin binding (3, (5) (6) (7) . EPCs can be ex vivo-expanded out of isolated peripheral blood mononuclear cells (PBMCs) or obtained by cultivation of CD34 + -or CD133 + -hematopoietic progenitors (1) (2) (3) (5) (6) (7) (8) (9) (10) . EPCs were shown to integrate into blood vessels and improve neovascularization of ischemic hind limb and ischemic hearts in animals (1, 2, 10, 11) .
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Clinical studies demonstrated that the number and function of EPCs are adversely affected by classical risk factors for coronary artery disease (CAD) such as smoking, hypercholesterolemia, and diabetes (11) (12) (13) , thus potentially limiting their capacity to contribute to neovascularization in patients with ischemic heart disease. The mechanisms underlying the reduced number of EPCs in patients with CAD are unknown. One conceivable mechanism limiting the number of EPCs might be reduced survival due to the induction of apoptosis. Although EPCs are less sensitive to apoptosis induction as compared with mature endothelial cells such as human umbilical vein endothelial cells (HUVECs) or human dermal microvascular endothelial cells (HMVECs) (14, 15) , apoptosis might be an important regulatory cellular mechanism under pathophysiological conditions. Indeed, EPCs were shown to be extremely sensitive to the growth-inhibitory effects of angiostatin, an antiangiogenic cleavage fragment of plasminogen (16) . In contrast, the proangiogenic growth factor VEGF increases the number of EPCs both in vitro and in vivo (17) . Likewise, statins enhance the number of EPCs in vitro, in mice, and in patients with stable CAD (6, 7, 18) . Notably, the ex vivo effects of statins on EPC number are equipotent to the effects of vascular endothelial growth factor (VEGF) (7, 18) . Both statins as well as VEGF appear to exert their beneficial effects on EPCs via the PI3K/Akt pathway (7, 18) .
The serine/threonine kinase Akt is well established to play an important role in endothelial cell biology and angiogenesis by activating antiapoptotic, prosurvival signaling cascades (7, (19) (20) (21) . Akt-dependent phosphorylation leads to the posttranscriptional activation of the endothelial NOsynthase via phosphorylation of the amino acid Ser 1177, which has been described as an important antiapoptotic signaling pathway in endothelial cells (22, 23) . In addition, Akt regulates the activity of a variety of other targets, including the proapoptotic protein Bad, caspase-9, and members of the forkhead transcription factor family such as FOXO1, FOXO3a, and FOXO4 (24) (25) (26) (27) (28) . FOXOs regulate the transcription of the cell cycle inhibitor p27 as well as the proapoptotic Fas ligand and the Bcl-2-like-protein Bim (28) (29) (30) . Bim was previously shown to limit cytokine-initiated survival signaling in hematopoietic progenitor cells, as well as to control granulocyte and lymphocyte survival (31) (32) (33) . Akt-dependent phosphorylation leads to inhibition of forkhead transcription factor activity and, thereby, prevents apoptosis signaling (27, 28) .
Increased reactive oxygen species generation in vascular cells is a hallmark of all classical risk factors for CAD (34, 35) . Likewise, reactive oxygen species were shown to interfere with FOXO activity (36) . Therefore, we further examined whether FOXO-dependent regulation of Bim is involved in the protective effects of statins on oxidative stress-induced apoptosis of EPCs. The results of the present study demonstrate that Bim plays a pivotal role for apoptosis induction in EPCs. Moreover, PI3K/Akt-dependent inhibition of FOXO4, the predominant transcription factor of the forkhead family expressed in EPCs, accounts for the suppression of Bim expression and inhibition of EPC apoptosis by statins.
MATERIALS AND METHODS

Materials
Ly294002 (Biomol, Hamburg, Germany), mevalonate (Fluka, Buchs, Switzerland) and LNMA (Alexis, Grünberg, Germany) were preincubated 30 min before statin stimulation. VEGF was purchased from Calbiochem (Schwalbach, Germany), ZVAD-fmk from Bachem (Weil am Rhein, Germany), H 2 O 2 from Merck (Darmstadt, Germany), and atorvastatin was kindly donated by Goedecke/Parke-Davis (Freiburg, Germany). Mevastatin was activated as described previously (21) .
EPC culture assay
Mononuclear cells (MNCs) were isolated by density gradient centrifugation with Biocoll from peripheral blood of healthy human volunteers according to Vasa et al. (6) . Immediately following isolation, 8 × 10
6 MNCs/ml medium were plated on culture dishes coated with human fibronectin (Sigma, Taufkirchen, Germany) and maintained in endothelial basal medium (EBM; CellSystems, St. Katharinen, Germany) supplemented with EGM SingleQuots and 20% fetal calf serum (FCS). After 3 days in culture, nonadherent cells were removed by thorough washing with phosphate-buffered saline (PBS) and adherent cells were incubated in fresh medium with or without atorvastatin for 24 h before investigating EPC apoptosis by FACS analysis. EPCs were characterized by dual staining for 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyaninelabeled acetylated low-density lipoprotein (DiLDL) and lectin and by the expression of endothelial marker proteins KDR, VE-cadherin, eNOS, and von Willebrand factor (12) .
Cell culture
Pooled HUVECs were purchased from CellSystems (St. Katharinen, Germany) and cultured in endothelial basal medium as described previously (21) . HMVECs were purchased from CellSystems and cultured according to the manufacturer's instructions in endothelial basal medium-2 (EBM-2; CellSystems). CD34 + cells were isolated as described previously (7) . HEK 293 cells were maintained in Dulbecco's modified Eagle's medium containing 10% FCS and penicillin-streptomycin.
Detection of apoptosis by FACS analysis
The adherent cells were detached with trypsin, washed in PBS, and incubated with 2.5 µl Annexin-PE and 2.5 µl 7AAD for 15 min at room temperature according to the manufacturer (Annexin V-PE apoptosis kit, PharMingen, Heidelberg, Germany) and analyzed by FACS using a FACS SCAN flow cytometer and Cell Quest software (BD Biosciences, Heidelberg, Germany).
Detection of apoptosis by DAPI staining
Cell culture dishes were centrifuged (10 min, 700g), fixed in 4% formaldehyde, and stained with 4′,6-diamidino-phenylindole (DAPI; 0.2 µg/ml in 10 mmol/l Tris-HCl, pH 7.0, 10 mmol/l EDTA, 100 mmol/l NaCl) for 20 min. Five hundred cells were counted by two independent blinded investigators, and the percentage of apoptotic cells per total number of cells was determined (37) .
Microarray analysis
The protocol for sample preparation and microarray processing is available from Affymetrix (Santa Clara, CA). Data were analyzed with the software GeneSpring version 3.0 (Silicon Genetics, San Carlos, CA) as described previously (38) .
Western blot analysis
For determination of protein expression, cells were lysed as described previously (21) . Proteins (50 µg/lane) were loaded onto SDS-polyacrylamide gels and blotted onto PVDF membranes. Western blots were performed using antibodies directed against phospho-FOXO4/FOXO1/FOXO3a (#9464; 1:200; Cell Signaling, Frankfurt, Germany) or phospho-AFX (#9471; Cell Signaling), total FOXO4 (1:250; Santa Cruz Biotechnology, Heidelberg, Germany), Bim (1:500; BD Biosciences), Bad (1:500; BD Biosciences), or GFP (1:2000; Invitrogen, Karlsruhe, Germany). Enhanced chemiluminescence was performed according to the manufacturer's instructions (Amersham, Freiburg, Germany). Then, the blots were reprobed with tubulin (1:2000; Neomarkers, Asbach, Germany) or actin (1:4000; Sigma). The autoradiographies were scanned and semiquantitatively analyzed.
Plasmid transfection
Plasmids encoding human full-length BimEL (BimEL-forward, 5′ ccg ctc gag atg gca aag caa cct tct gat gta a 3′; BimEL-reverse, 5′ cgg gat cca tgc att ctc cac acc agg cgg 3′) were cloned by PCR from cDNA of EPCs or HUVECs into a pEGFP-vector (Clontech, Heidelberg, Germany). Plasmid encoding constitutive active HA-tagged FOXO4-A3 (T28, S193, and S258 mutated to A (39) were kindly donated by Dr. B. M. Burgering (Utrecht, The Netherlands). FOXO4-A3 was subcloned as a fusion protein in the pEGFP-vector (Clontech, Heidelberg, Germany). Transient transfection of EPCs was performed by electroporation using the Nucleofector kit ("CD34 cell solution"; Program T01; 5 µg plasmid/1 × 10 6 cells; Amaxa Biosystems, Köln, Germany). Transient transfection of HUVECs was performed by incubation of 3.7 × 10 5 cells/6 cm well with 3 µg of plasmid as described previously (22) using Superfect according to the manufacturer's instructions (Qiagen, Hilden, Germany). HEK 293 cells were transfected with Superfect according to the manufacturer's instructions (Qiagen).
Chromatin immunoprecipitation (ChIP)
The ChIP assay was performed as described previously (40) . Briefly, EPCs were transiently transfected as described above. After 4 h, EPCs were cross-linked for 10 min by directly adding 1% formaldehyde to the culture medium. The fixed cells were lysed with lysis buffer (1% Triton X-100, 0.32 M sucrose, 5 mM EDTA, 1 mM PMSF, 1 µg/ml leupeptin, 10 mM Tris/HCl, pH 8) and sonified 5 times for 10 s with output 5 (Branson Sonifire 450, Branson, Danbury, CT). For chromatin immunoprecipitation, cell lysates were incubated with an antibody against GFP (Invitrogen) to precipitate the GFP-FOXO4-A3 fusion protein. The isolated precipitated DNA was amplified by PCR with primers corresponding to a ≈330 bp fragment of the human Bim promoter or human monocyte chemoattractant protein-1 (MCP-1) promoter. Genomic DNA was used as positive control.
Luciferase assay
HEK 293 cells were cotransfected with HA-tagged FOXO4-A3 and luciferase under the control of the human Bim promoter (-3701/-2776 bp) cloned into the pGL3-enhancer vector (Promega, Mannheim, Germany). After 18 h, cells were lysed with 1× reporter lysis buffer (Promega), and a single freeze-thaw cycle was performed. The cells were scraped and centrifuged for 2 min at 2000g. Then, measurement of the luciferase activity was analyzed with a Lumat LB9510 luminometer (Berthold, Pforzheim, Germany) as described previously (41) .
Statistical analysis
Data are expressed as mean ± SE from at least three independent experiments. Statistical analysis was performed by t test. ANOVA was performed for serial analyses.
RESULTS
Statins prevent H 2 O 2 -induced apoptosis of EPCs
EPCs were isolated as described previously (7), and expression of endothelial marker proteins such as VE-cadherin, VEGFR-2 (KDR), and the endothelial NO-synthase was confirmed (12) . More than 80% of the EPCs were positive for endothelial markers under our cultivation conditions (12) . In addition, EPCs were double-positive for DiLDL uptake and von Willebrand factor expression (6), and EPCs had the potency to form vessel structures (21) and endothelial colonies (42) . Incubation of EPCs with H 2 O 2 for 24 h resulted in a dose-dependent increase of apoptosis as assessed by Annexin-V measurement (Fig. 1A) . Likewise, the number of ex vivo differentiated attached DiLDL/lectin double-positive cells was reduced to 48 ± 4% of control in the presence of 500 µM H 2 O 2 . Preincubation of EPCs with the HMG-CoA reductase inhibitor atorvastatin for 24 h significantly reduced H 2 O 2 -induced apoptosis in a dose-dependent manner, with maximal inhibitory effects achieved with 0.01 µM (Fig. 1B, data not shown) . Consistently, mevastatin significantly blocked H 2 O 2 -induced apoptosis (Fig. 1B) , suggesting a class effect of statins. The antiapoptotic effect of atorvastatin and mevastatin was partially reversed by the product of the HMG-CoA reductase, mevalonate (Fig. 1B) .
Statins inhibit EPC apoptosis in a PI3K/Akt-dependent, but NO-independent, manner
Statins and VEGF activate the antiapoptotic PI3K/Akt pathway in EPCs (7, 18) . Therefore, we investigated the role of the PI3K/Akt pathway for EPC apoptosis. The PI3K inhibitor Ly294002 abolished the apoptosis-inhibitory effect of atorvastatin in EPCs (Fig. 1C) . Furthermore, VEGF, which is also known to activate the PI3K/Akt pathway, significantly reduced H 2 O 2 -induced EPC apoptosis in a PI3K/Akt-dependent manner (Fig. 1C, data not shown) . In contrast, inhibition of one antiapoptotic downstream pathway of Akt, the NO synthase (43) , by blockade with LNMA did not reverse the apoptosis inhibition by atorvastatin (Fig. 1C) , suggesting a PI3K/Aktdependent, but NO-independent, antiapoptotic signaling pathway, which is activated by statins.
Statins phosphorylate the forkhead factor FOXO4
Because forkhead transcription factors are direct downstream targets of Akt and are inactivated by Akt-dependent phosphorylation of serine/threonine residues (27, 28), we investigated whether statins may phosphorylate and, thereby, inactivate the forkhead transcription factors. Therefore, we first characterized the expression pattern of the forkhead factors FOXO1, FOXO3a, and FOXO4 in EPCs. EPCs expressed higher mRNA levels of FOXO4 as compared with HUVECs (EPC: 1.2±0.3 vs. HUVEC: 0.7±0.3 normalized fluorescence intensity; n=3) as assessed by microarray assay. Moreover, Western blot analysis demonstrated a higher expression of FOXO4 in EPCs, whereas the expression of FOXO1 and FOXO3 is low or absent ( Fig. 2A) . Thus, we focused on the role of FOXO4 in EPC apoptosis.
Atorvastatin dose-and time-dependently phosphorylated FOXO4 in EPCs with maximum effects at 60 min (154.5±30.6% of control; Fig. 2B, 2C , data not shown). Atorvastatin-induced phosphorylation was blocked by the PI3K inhibitor Ly294002 (Fig. 2B, 2C ). Statin-mediated increase of FOXO4 phosphorylation was similar to the effects achieved by VEGF or SCF, which are known activators of the PI3K/Akt pathway in endothelial and hematopoietic stem cells (Fig.  2D, 2E ).
Statins down-regulate Bim in EPCs
The proapoptotic protein Bim is a major downstream target of the forkhead transcription factor family, which has previously been implicated in Akt-dependent regulation of hematopoietic stem cell survival (32) . Therefore, we analyzed the potential involvement of Bim in apoptosis of EPCs. Thus far, 12 Bim isoforms with different proapoptotic potencies have been described: BimS, BimL, BimEL, Bimα1-3, Bimβ1-5, and Bimγ (44) (45) (46) (47) . The RNA expression was identified by sequencing of RT-PCR products obtained with primers directed against the 5′ and 3′ region of full-length BimEL. The resulting bands were identified as BimEL, BimL, BimS, and Bimβ2 according to the database cDNA sequences (accession numbers AF032458, AF032457, and AB071198, respectively). Western blot analysis demonstrated that EPCs express the Bim isoforms BimEL, BimL, and BimS similar to the protein expression pattern of CD34 + cells. In contrast, HUVECs and HMVECs mainly express the BimEL isoform (Fig. 3A) .
Incubation of EPCs with H 2 O 2 significantly up-regulated the expression of BimEL (Fig. 3B, 3C) . Likewise, expression of BimL was increased after stimulation with H 2 O 2 , although to a minor extent (Fig. 3B, 3C ). In contrast, the proapoptotic BH3-only protein, Bad, was not regulated (Fig.  3D) , suggesting a rather selective regulation of Bim. Coincubation with atorvastatin or VEGF dose-dependently down-regulated BimEL (0.01 µM atorvastatin: 39.5±7.6% of control; 0.1 µM atorvastatin: 34.9±7.2% of control) and Bim L expression and abrogated the H 2 O 2 -induced increase in BimEL and BimL expression in EPCs (Fig. 3B, 3C , 3E, 3F and data not shown). The reduction of Bim expression by atorvastatin was dependent on the PI3K pathway, as demonstrated by the inhibitory effect of the PI3K-inhibitor Ly294002 (Fig. 3E, 3F ).
Overexpression of FOXO4 activated the Bim promoter and stimulated its expression
Having demonstrated that atorvastatin regulates phosphorylation of FOXO4 and expression of Bim, we investigated the interaction of FOXO4 with the Bim promoter in EPCs using chromatin immunoprecipitation assays. After cross-linking, immunoprecipitates of overexpressed GFPtagged FOXO4-A3 were subjected to subsequent PCR using primers directed against the Bim promoter sequence. The Bim promoter interacted with FOXO4 in EPCs (Fig. 3G) . Genomic DNA was used as positive control. In contrast, FOXO4 did not interact with the promoter of MCP-1 (data not shown).
To prove that FOXO4 principally activates the transcription of Bim, we performed a luciferase reporter gene assay. We cloned the luciferase reporter gene under the control of the human Bim promoter. A construct (-3701/-2776 bp) of the Bim promoter was transfected together with a nonphosphorylatable, constitutively active FOXO4-A3 (T28, S193, and S258 mutated to A [39] ) in HEK 293 cells. FOXO4-A3 overexpression increased luciferase activity of the -3701/-2776 bp Bim promoter construct compared with cotransfection of the empty vectors (Fig. 3H) . Similar results were obtained when using EPCs (data not shown). To further confirm the regulation of Bim by FOXO4 transcription factor, we transfected EPCs with GFP-FOXO4-A3 and analyzed Bim expression. As shown in Fig. 3I and 3J, overexpression of GFP-FOXO4-A3 induced the expression of Bim in EPCs. Importantly, the induction of Bim expression in FOXO4-A3 overexpressing EPCs could only be detected in the presence of the pan-caspase inhibitor ZVADfmk, thus demonstrating the potent proapoptotic effect of FOXO4 in EPCs.
Statins do not prevent EPC apoptosis induced by overexpression of FOXO4 or Bim
Finally, we addressed the causal role of FOXO4 phosphorylation and Bim down-regulation for statin-induced support of EPC survival. For that purpose, we overexpressed GFP-BimEL or a nonphosphorylatable, constitutively active GFP-FOXO4-A3 construct by using electroporation of EPCs, which revealed a transfection efficiency of ~21±5% (Fig. 4A) . Overexpression of BimEL or nonphosphorylatable FOXO4-A3 construct potently increased apoptosis of EPCs (Fig.  4C) . The drastic proapoptotic effect was underlined by the finding that the expression of GFPBimEL or GFP-FOXO4-A3 in EPCs could be detected only in the presence of the caspaseinhibitor ZVAD-fmk (Fig. 4B) . Coincubation with atorvastatin did not prevent BimEL-or FOXO4-induced apoptosis (Fig. 4C) , consistent with the concept that statins mediate the antiapoptotic effect via FOXO4-dependent transcriptional regulation of Bim.
Role of FOXO4 and Bim in HUVECs
To further substantiate a pivotal role for FOXO4-dependent regulation of Bim to mediate the antiapoptotic effects of statins in EPCs, we made use of the differential expression profile of the forkhead factor family members in HUVECs compared with EPCs (see Fig. 2 ). Statins had no effect on Bim expression in HUVEC (Fig. 5A) , although statins activate Akt in HUVECs (18, 21, data not shown). Surprisingly, overexpression of a constitutively active GFP-FOXO4-A3 did not increase apoptosis in HUVECs (Fig. 5B, 5C ). Likewise, overexpression of GFP-BimEL induced only a minor nonsignificant increase in apoptosis of HUVECs, although the transfection efficiency was significantly higher in HUVECs compared with EPCs (33±6% vs. 21±5%, respectively). Thus, Akt-dependent signaling pathways regulating apoptosis differ between mature endothelial cells as compared with EPCs. The FOXO4-dependent regulation of BimEL appears to be a rather specific signaling pathway in EPCs.
DISCUSSION
Increasing evidence suggests that EPCs play a crucial role for neovascularization and vascular regeneration in the adult, processes that are critically required in patients with ischemic heart disease. However, EPC levels and functions are impaired in patients with CAD and diabetes (11) (12) (13) . Although the molecular mechanisms underlying the decrease in EPCs are not yet clear, the induction of the apoptotic cell death program in EPCs could contribute to the reduction in EPC numbers. Indeed, the data of the present study demonstrate that reactive oxygen species, which are known to be increased in patients with CAD or diabetes, profoundly reduce the number of viable EPCs by inducing apoptosis. Although recent data demonstrated that EPCs are more protected against oxidative stress-induced apoptosis as compared with HUVECs, high levels of H 2 O 2 (≥500 µM) increased apoptosis ~2.5-to 4-fold in EPCs (14) . Likewise, the proatherosclerotic factor oxidized LDL reduced EPC numbers to a similar extent (data not shown), suggesting that apoptosis is one regulatory mechanism for EPC survival. Thereby, upregulation of the forkhead factor-dependent proapoptotic protein Bim appears to play a pivotal role for apoptosis signaling in EPCs. Importantly, statin-mediated activation of the PI3K/Akt signaling pathway abrogated increased Bim expression and apoptosis induction in EPCs by phosphorylation-mediated inactivation of FOXO4, thus establishing the Akt-FOXO4-Bim signaling pathway as a major potential therapeutic target to improve EPC numbers and function in patients with ischemic heart disease.
The inhibition of H 2 O 2 -induced apoptosis of EPCs by HMG-CoA reductase inhibitors (statins) or the endothelial cell growth factor VEGF is in accordance with previous reports, which demonstrated an increase in EPC numbers in vitro, in animals, and in patients with CAD (6, 7, 18, 48) . The statin-mediated prevention of H 2 O 2 -induced up-regulation of the Bim isoforms BimEL and BimL appears to be rather specific, because other BH3-only proteins such as Bad were not regulated by statin incubation. The down-regulation of Bim involves the statin-induced phosphorylation of the forkhead transcription factor FOXO4, which prevents its translocation to the nucleus and thereby inhibits Bim expression (28, 30) . Likewise, the expression of other known FOXO target genes such as p27 are decreased by statin treatment in EPCs (42) . The upstream signaling pathways, by which statins regulate forkhead transcription factors, involve the activation of the PI3K/Akt pathway. Previous studies by us and others demonstrated that statins stimulate the activation of Akt in vitro and in vivo (7, 20, 21) . Akt, in turn, phosphorylates and inactivates FOXO4 and thereby prevents FOXO4 translocation to the nucleus (27) . The causal role of FOXO4 phosphorylation was demonstrated in the present study by using a FOXO4 construct, which lacks the known Akt phosphorylation motifs and thereby prevents Akt-dependent inactivation.
FOXO transcription factors are known to regulate the expression of Bim, Fas ligand, and p27 (28) (29) (30) . In addition, Ramaswamy and coworkers demonstrated two different mechanisms of FOXO-dependent gene regulation (49) . Overexpression of different FOXO1 (FKHR) mutants and subsequent transcriptional profiling revealed a direct regulation via DNA binding of FOXO1 to insulin response sequences (IRS) or IRS-like promoter elements as well as an indirect regulation, including cofactors and/or IRS-independent undefined promoter elements (49) . The data of the present study showed a transcriptional activation of the Bim promoter by FOXO4 overexpression. This is in accordance with a recent study demonstrating that FOXO3a directly activates Bim gene expression and promotes apoptosis in neuronal cells (50) . The Bim promoter construct used in the present study contains one potential FOXO binding site (GTAAACAC) that closely matches a consensus sequence (GTAAACAA) described previously (51) and is identical to a conserved FOXO binding site described in the rat Bim promoter (50).
Little is known about the individual biological function of the different forkhead transcription factors. It has been shown that all of the three forkhead factors are able to bind to insulinresponsive elements in promoter constructs and transactivate FasL or IGFBP-1 reporter constructs (27, 28, (52) (53) (54) . FOXO1, FOXO3a, and FOXO4 contain Akt phosphorylation sites at serine and threonine residues (55) . Moreover, overexpressed FOXO1, FOXO3a, and FOXO4 were shown to regulate Bim expression in hematopoietic cells (30) . These data would suggest a similar effect of the different forkhead transcription factors on the target genes. However, first studies indicate that the biological activity of FOXO1 and FOXO3a might differ from FOXO4 (55) . Moreover, the expression profile is different. FOXO4 was shown to be highly expressed in hematopoietic cells (55, 56) , whereas FOXO1 and FOXO3a are expressed more ubiquitously (57, 58) . This is consistent with the findings of the present study, which demonstrates a higher expression of FOXO4 in EPCs, which more closely resemble the hematopoietic cell type compared with mature endothelial cells. However, the differences in apoptosis signaling between EPCs and mature HUVECs may also involve additional downstream signals beyond the differential expression of forkhead transcription factors. Whereas our data rule out a differential alternative splicing of Bim (44, 45) , overexpression of BimEL induced only a minor apoptotic response in HUVECs as compared with EPCs. Since the expression levels and transfection efficiency of BimEL were in favor for HUVECs, this would imply a possible posttranscriptional inactivation of Bim in HUVECs. Indeed, the proapoptotic activity of Bim is known to be posttranscriptionally regulated by association with the dynein motor complex (59) . Another possibility could be the phosphorylation of BH3-only proteins as it has been shown for BAD or Bid (60, 61) .
Taken together, the data of the present study demonstrate that statins inhibit apoptosis of EPCs by down-regulation of the proapoptotic protein Bim. The down-regulation of Bim involves the statin-induced phosphorylation of the forkhead factor FOXO4, which inactivates the transcription factor and thereby prevents Bim expression. The potential importance of FOXO4 for regulation of EPCs is underlined by the finding that EPCs derived from patients with CAD reveal significantly higher expression levels of FOXO4 as compared with healthy controls and showed increased basal apoptosis (data not shown). These data suggest that selective targeting of the FOXO4-Bim pathway may provide an important therapeutic strategy to improve EPC function in patients with CAD.
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